Original article

Body composition and lipodystrophy in prepubertal HIV-infected children

Cecilia Zanin Palchetti, Rose Vega Patin, Aída de Fátima Thomé Barbosa Gouvêa, Vera Lúcia Szejnfeld, Regina Célia de Menezes Succi, Fernanda Luisa Ceragioli Oliveira*

Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, SP, Brazil

A R T I C L E   I N F O

Article history:
Received 31 August 2011
Accepted 28 October 2012
Available online 11 January 2013

Keywords:
HIV
Child
Lipodystrophy
Body composition
Anthropometry

A B S T R A C T

Objective: To identify lipodystrophy in prepubertal HIV-infected children using anthropometric parameters and body composition assessment.
Methods: Cross-sectional study including 40 prepubertal HIV-infected children of both genders seen at the Care Center of the Division of Pediatric Infectious Diseases – Universidade Federal de São Paulo, São Paulo city, Brazil, was carried out from August to December 2008. Age, clinical and immunological status, prophylaxis, transmission and highly active antiretroviral therapy were recorded. Body mass index z-score and height-for-age z-score were calculated to characterize the nutritional status. Circumferences were measured with flexible tape and skinfolds were assessed by an adipometry. Fat mass and lean mass were determined by dual-energy X-ray absorptiometry. Presence of clinical signs of lipodystrophy was assessed by a trained clinician. Data were analyzed using SPSS 12.0 software.
Results: The mean age and standard deviation were 9.8 (1.2) years, 50% were girls and 82.5% children from B and C categories. Clinical lipodystrophy and dislipidemia were present in 27.5% and 70%, respectively. The trunk to arm ratio and the limb to trunk ratio had positive association with lipodystrophy. Patients with lipodystrophy had short stature, higher triglycerides values and lower HDL-cholesterol.
Conclusion: The ratios obtained by skinfolds and dual-energy X-ray absorptiometry measurements can be considered as indicators of preclinical lipodystrophy. The cutoff points have not been determined yet; however, continuous assessment may be useful to identify early body composition changes.

© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND

Introduction

The highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality in HIV-infected children. A U.S. multicenter study showed that, between 1994 and 2000, the death rate decreased from 7.2 to 0.8 per 100 children/year, remaining stable until 2006.1 In Brazil, probability of survival to 60 months has increased from 52.8% among children diagnosed during the period between 1983 and 1998 to 86.3% among children born from 1999 to 2007.2 Assuredly, in addition to preserve or restore the immune system, the use

* Corresponding author at: UNIFESP/EPM, Departamento de Pediatria, Rua Loefgreen, 1647, 04040-032, São Paulo, SP, Brazil.
E-mail address: fernandalco@gmail.com (F.L.C. Oliveira).
1413-8670 © 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
http://dx.doi.org/10.1016/j.bjid.2012.12.001
of HAART also contributes to maintain or improve weight for height growth.\(^3\)

Nonetheless, HIV infection itself and the use of antiretroviral therapy cause clinical and metabolic changes initially described in adults in the late 90s\(^4\) and subsequently observed in children and adolescents.\(^5\) Due to precocity and large exposure to the drug, especially in infections acquired by vertical transmission, this population shows higher risks of developing adverse effects of antiretroviral therapy.\(^6\)

Among other metabolic side effects of antiretroviral therapy, we mention the lipodystrophy syndrome, which comprises lipodystrophy, dyslipidemia, insulin resistance and cardiovascular risk.\(^7\) Lipodystrophy is identified and characterized by the use of clinical parameters, which causes several difficulties.\(^7,8\) Anthropometric measurements and assessment of body composition are useful instruments to monitor the evolution of growth, also being useful to identify the presence of clinical and metabolic changes.\(^9\) Therefore, this study aims to identify lipodystrophy in prepubertal HIV-infected children through anthropometric measurements and body composition assessments.

**Methods**

We carried out a cross sectional study with 52 prepubertal children (7–12 years old), both genders, seen at the Care Center of the Division of Pediatric Infectious Diseases (CEADIPe) of the Department of Pediatrics of UNIFESP/EPM from August to November 2008. Children with genetic syndrome or neuropathy were not included. One hospitalized patient died, five had neuropathy and six were not allowed by the caregiver to participate in the study. Thus, the final sample totaled 40 patients. The study was approved by the Research Ethics Committee of the Universidade Federal de São Paulo and initiated upon consent in writing of parents or guardians.

Pubertal stage was assessed by the pediatrician, who used, as a criterion, the development of the secondary sexual characteristics proposed by Marshall and Tanner,\(^10\) including the study children and adolescents who showed staging.\(^1\) In order to classify the disease, we used the clinical parameters and immunological categories proposed by the Ministry of Health,\(^3\) which adopted the guidelines from the Centers for Disease Control and Prevention (CDC),\(^11\) in addition to inclusion of pulmonary tuberculosis as a criterion in clinical category B.

Data on identification, age, type of transmission, prophylaxis, patient’s legal caregiver and/or guardian and antiretroviral regimen were collected from the medical records of these patients. Clinical lipodystrophy was clinically identified by the pediatrician, showing three characterizations: lipoatrophy, lipo hypertrophy and mixed lipodystrophy.\(^12\)

Weight and height measurements were used to calculate the body mass index z-score (BMI) and height for age z-score (HAz), pursuant to the reference standard and recommendation of the World Health Organization.\(^13\) Skinfolds were measured by using an adipometer under the brand Lange® (Beta Technology Inc., Santa Cruz, CA, USA) with precision of 1 mm, and circumferences were measured with a flexible, non-extendable tape graduated in 0.1-cm. Trunk to arm ratio was calculated through the sum of the subscapular and suprailiac skinfold divided by the value resulting from the sum of biceps and triceps skinfolds.\(^12\) Body composition was assessed through dual-energy X-ray absorptiometry (DXA) by only one trained technician (equipment LUNAR® DPX-L, pediatric software, version 1.5). The ratio limb to trunk was obtained by adding the fat (g) in arms and legs and dividing it by the fat value (g) in trunk.

HIV viral load was determined through the RT-PCR technique (Cobas Amplipcr HIV-1 Monitor®, Test, version 1.5) and T CD4 and T CD8 lymphocytes were assessed through flow cytometry (BD FACSCalibur®). The lipid profile was determined through reflectance spectrophotometry – colorimetry – 540 nm (Vitros Systems Chemistry 750 XRC – Ortho-Clinical Diagnostics, Inc. – Johnson & Johnson Company, New York, NY, USA), using the cutoffs proposed by Kwitterovich.\(^14\) Blood glucose was measured through the enzymatic method using hexokinase and glucose-6-phosphate dehydrogenase enzyme (Advia Chemistry System 1650 – Bayer) and insulin through an immunoenzymatic method (Tosoh–Tosoh Corporation, Tokyo, Japan). Fasting insulin and blood glucose were used to calculate the homeostatic model assessment-insulin resistance (HOMA-IR), which characterizes insulin resistance when HOMA-IR > 3.\(^5\) Skeletal muscle mass was calculated pursuant to Heymsfield et al.\(^15\)

For statistical analysis, we used the Statistical Package for the Social Sciences (SPSS) program version 12.0. To compare qualitative variables, we used the Chi-square test or Fisher’s Exact test. To compare quantitative variables, we used Student’s t-distribution test. Shapiro–Wilk test was used to assess the normality of continuous quantitative variables. Those showing no regular distribution were transformed into logarithm (log\(_{10}\)) for the statistical tests. We computed the Pearson’s correlation coefficient in order to show the degree of linear correlation between the variables. A linear regression model was prepared to investigate the determinants of lipodystrophy. The trunk to arm ratio was used as a dependent variable. A correlation matrix was developed, providing that the entry in the model followed the ascending order with value p < 0.20. The variables that adjusted the model and remained significant were maintained in the final model. Values of p < 0.05 were deemed significant.

**Results**

In this study, the final sample comprised 40 prepubertal children, where 50% of the sample were female, with an average age and age standard deviation of 9.8 ± 1.2 years. HIV infection occurred through vertical transmission in 39 (97.5%) of the prepubertal children, provided that 25 (56.4%) did not receive any type of prophylaxis during the gestational and perinatal stage and the first months of life. With respect to clinical and immunological classification, 33 (82.5%) were linked to clinical parameters B and C and 16 (40%) to immunological classification 3. Clinical lipodystrophy was identified in 11 (27.5%, IC 95%: 14.6–43.9) patients, three (7.5%) characterized as lipo hypertrophy, four (10%) as lipoatrophies and four (10%) as mixed lipodystrophy. Antiretroviral therapy combined with three drugs was used by 30 (75%) study patients and 21 of them (52.5%) used therapeutic regimen with protease inhibitor.
Table 1 – Characterization, nutritional status, antiretroviral drug, metabolic changes and immunological and biochemical parameters of HIV-infected prepubertal children with and without lipodystrophy.

| Variables                        | With lipodystrophy (n = 11) | Without lipodystrophy (n = 29) | p    |
|---------------------------------|------------------------------|---------------------------------|------|
| Male*                           | n (%)                        | n (%)                           |      |
| Vertical transmission*          | 4 (36.4)                     | 16 (55.2)                       | 0.288|
| Clinical classification B and C*| 11 (100)                     | 28 (96.6)                       | 0.999|
| Nutritional status              |                              |                                 |      |
| Eutrophy*                       | 10 (90.9)                    | 23 (79.3)                       | 0.650|
| Short stature*                  | 4 (36.4)                     | 2 (6.9)                         | 0.020|
| Used medications                |                              |                                 |      |
| PI*                             | 6 (54.5)                     | 15 (51.7)                       | 0.873|
| NRTI*                           | 10 (90.9)                    | 24 (82.8)                       | 0.999|
| NNRTI*                          | 3 (27.3)                     | 7 (24.1)                        | 0.295|
| Metabolic changes               |                              |                                 |      |
| Hypertriglyceridemia*           | 6 (54.5)                     | 10 (34.5)                       | 0.295|
| Hypercholesterolemia*           | 1 (9.1)                      | 12 (41.4)                       | 0.068|
| Increase in LDL-c*              | 1 (9.1)                      | 6 (20.7)                        | 0.650|
| Decrease in HDL-c*              | 5 (45.5)                     | 22 (75.9)                       | 0.128|
| Hyperglycemia*                  | 0                            | 2 (6.9)                         | 0.999|
| HOMA-IR > 3*                    | 1 (9.1)                      | 0                              | 0.999|
| Average (SD)                    | 10.2 (1.1)                   | 9.6 (1.2)                       | 0.179|
| Age (years)*                    | 10.2 (1.1)                   | 9.6 (1.2)                       | 0.179|
| Immunological parameters        |                              |                                 |      |
| Viral load (log)b                | 3.2 (1.3)                    | 2.8 (1.3)                       | 0.310|
| CD4 (cells/mm³)b                 | 939.1 (923.1)                | 740.8 (409.7)                   | 0.349|
| CD8 (cells/mm³)b                 | 1199.1 (313.4)               | 1059.2 (464.6)                  | 0.497|
| Biochemical parameters          |                              |                                 |      |
| Triglycerides (mg/dL)b           | 160.6 (87.9)                 | 112.7 (54.4)                    | 0.044|
| Total cholesterol (mg/dL)b       | 142.9 (33.6)                 | 158.4 (36.3)                    | 0.227|
| LDL-cholesterol (mg/dL)b         | 76.6 (34.9)                  | 88.3 (28)                       | 0.273|
| HDL-cholesterol (mg/dL)b         | 34.6 (8.6)                   | 45.9 (14.3)                     | 0.019|
| Blood glucose (mg/dL)b           | 82.3 (6)                     | 84.8 (9.4)                      | 0.422|
| HOMA-IRb                         | 1.2 (1.1)                    | 0.7 (0.5)                       | 0.150|

HOMA-IR, homeostatic model assessment-insulin resistance; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors. Bold values mean the values that presented statistical difference.

* Chi-square test or Fisher’s Exact test.

(Pi). Time of exposure to antiretroviral therapy in this population was 7.8 ± 2.4 years. As for the nutritional condition, 33 (82.5%) were eutrophic, 6 (15%) overweight/obese and 34 (85%) showed proper height. The prevalence of dyslipidemia in the study population was 70% (28 children). Regarding metabolic changes, 16 patients (40%) showed hypertriglyceridemia, 13 (32.5%) hypercholesterolemia, 13 (32.5%) a decrease in HDL cholesterol serum levels and 7 (17.5) an increase in LDL cholesterol serum levels. Insulin resistance was found in 1 (2.5%) patient.

In Table 1, we compared clinical variables and immunological and laboratory parameters of patients in the presence or absence of lipodystrophy. The trunk to arm ratio, obtained through skinfolds, showed a strong association with the presence of lipodystrophy, as well as the ratio limb to trunk determined through DXA (Table 2). When correlated, these variables showed a moderate negative correlation (r = −0.69; p = 0.000) (Fig. 1).

With respect to waist circumference and other variables, we noted a positive correlation with trunk to arm ratio (r = 0.42; p < 0.007) and with zBMI (r = 0.68; p = 0.003) and a negative correlation with the limb to trunk ratio (r = −0.68; p = 0.000). The trunk to arm ratio also showed a positive correlation with insulin (r = 0.48; p = 0.001) and HOMA-IR (r = 0.45; p = 0.004), showing metabolic changes resulting from central adiposity. As for biochemical tests, T CD4 lymphocytes and viral load showed a positive and negative correlation with total cholesterol (r = 0.41; p < 0.008; r = −0.50; p = 0.001) and LDL cholesterol (r = 0.49; p = 0.001; r = −0.65; p = 0.000), respectively. Viral load also showed a negative correlation with HAZ (r = −0.47; p = 0.002).

The linear regression used the trunk to arm ratio as a control variable and showed association with the arm circumference (β = 0.71; p = 0.045; IC 95%: 0.017–1.41) and HOMA-IR (β = 0.14; p = 0.026; IC 95%; 0.018–0.271).

Discussion

Prevalence of lipodystrophy in the study population (27.5%) was similar to results obtained in other groups, such as the
Table 2 – Average and standard deviation of anthropometric measures/indexes and fat percentage (%) assessed through DXA of prepubertal HIV-infected children with and without lipodystrophy.

| Variables                              | With lipodystrophy (n = 11) Average (SD) | Without lipodystrophy (n = 29) Average (SD) | p      |
|----------------------------------------|------------------------------------------|---------------------------------------------|--------|
| zBMI                                   | -0.2 (1.7)                               | 0.0 (1.3)                                   | 0.764  |
| HAz                                    | -1.1 (1.7)                               | -0.7 (1.1)                                  | 0.532  |
| Waist circumference (cm)               | 64.7 (8.8)                               | 59.6 (6.5)                                  | 0.051  |
| Arm circumference (cm)                 | 19.1 (2.2)                               | 18.6 (2.8)                                  | 0.601  |
| Calf circumference (cm)                | 25.6 (2.1)                               | 26.1 (3.2)                                  | 0.633  |
| Triceps skinfold (mm)                  | 7.4 (1.6)                                | 8.8 (3.2)                                   | 0.079  |
| Biceps skinfold (mm)                   | 4.9 (2.3)                                | 6.0 (2.1)                                   | 0.184  |
| Subcapular skinfold (mm)               | 7.2 (3.5)                                | 6.3 (1.9)                                   | 0.316  |
| Suprailiac skinfold (mm)               | 7.7 (5.2)                                | 6.1 (2.9)                                   | 0.240  |
| Trunk to arm ratio                     | 1.2 (0.4)                                | 0.9 (0.2)                                   | 0.024  |
| Skeletal muscle mass index             | 5.36 (0.6)                               | 5.07 (0.7)                                  | 0.227  |
| Lean body mass DXA (%)                 | 79.9 (14.1)                              | 83.1 (8.2)                                  | 0.491  |
| Lean body mass DXA (kg)                | 25 (12.2)                                | 24.2 (4.4)                                  | 0.850  |
| Total fat DXA (%)                      | 17.88 (8.4)                              | 16.91 (8.2)                                 | 0.746  |
| Total fat DXA (kg)                     | 5.5 (4.12)                               | 5.25 (3.6)                                  | 0.860  |
| Arm fat DXA (%)                        | 10.8 (9.6)                               | 11.5 (7.7)                                  | 0.807  |
| Leg fat DXA (%)                        | 15.5 (6.8)                               | 21.1 (9.6)                                  | 0.085  |
| Trunk fat DXA (%)                      | 20.1 (10.7)                              | 18.1 (9.4)                                  | 0.564  |
| Android fat DXA (%)                    | 24.9 (13.7)                              | 17.7 (9.6)                                  | 0.066  |
| Gynoid fat DXA (%)                     | 23.5 (8.8)                               | 29.3 (9.2)                                  | 0.076  |
| DXA-limb to trunk ratio                | 0.7 (0.2)                                | 1 (0.2)                                     | 0.001  |

zBMI, body mass index z-score; HAz, height-for-age z-score; BIA, bioimpedance; DXA, dual-energy X-ray absorptiometry. Bold values mean the values that presented statistical difference.

US population (29%).17 Another Brazilian assessment found lipodystrophy in 14% of HIV-infected children.18

Scientific evidences suggest that lipohypertrophy and lipodystrophy itself are more frequent in pubescent children, as sexual maturity and hormonal factors may contribute to this outcome.12,19 The diagnosis of lipohypertrophy and mixed lipodystrophy in prepubertal children in this study may be explained by the advanced classification of the disease and high prevalence of dyslipidemia. Lipodystrophy, insulin resistance and dyslipidemia, with subsequent increase in cardiovascular risk, characterize the lipodystrophy syndrome, in which etiology seems to be related with some classes of antiretroviral drugs, such as PI and nucleoside reverse transcriptase inhibitors (NRTI); duration of drug administration; increase in viral load; low levels of CD4 and prior increase in serum levels of triglycerides and cholesterol.4,6

In this study population, there is a higher serum level of triglycerides and lower HDL cholesterol in patients with body fat redistribution. The European cohort related the presence of lipodystrophy with levels of triglycerides, insulin and blood glucose.20 A Spanish study with heterogeneous pediatric population (21 months to 18 years old) verified a higher prevalence of lipodystrophy within the higher age group and in the presence of hypertriglyceridemia, with no positive association with viral load, T CD4 lymphocyte, total cholesterol and glucose. With respect to classes of antiretroviral drugs, we did not note association with lipodystrophy. The current literature evidences conflicting data as to the presence of lipodystrophy associated with the use of PI. A US study with a population averaging 11.9 years showed no association21 between the drug use and this clinical change, while another Brazilian work, with a population averaging 9.1 years, verified a positive association between these two variables.22

The use of antiretroviral therapy plays a positive role as to maintenance or improvement of nutritional condition, however, in children with lipodystrophy, we noted a higher prevalence of short stature. Hormonal factors, nutritional condition, gastrointestinal and endocrine disorders, insufficient food intake and recurrent infection may also compromise height development23,24. The mechanism by which this impairment occurs is not very well described in the literature, and it is possible to find divergences between researchers and reviews with respect to this topic.23,25

HIV infection is also characterized by hormonal disorders, of which we highlight the impairment of growth hormone/insulin-like growth factor-1 (GH/IGF-1). There seems

Fig. 1 – Pearson’s correlation between the ratio limb to trunk obtained through DXA and trunk to arm ratio obtained through skinfolds (r = -0.69; p = 0.000). DXA, dual-energy X-ray absorptiometry.
changes in body composition, such as fat reduction in lower limbs and increase in visceral adiposity through DXA. Only 8/37 of these patients were provided with the same clinical and image diagnosis of lipodystrophy.6

The results of this study show limitations as it is a cross sectional study, which only considers variables at the moment of data collection, in addition to the limited sample regarding population seen at this clinic. Thus, it would be ideal to have a cohort study to better assess the metabolic side effects compared to changes in body composition. On the other hand, the study shows a homogeneous sample as to age, pubertal stage, severity of the disease and use of antiretroviral drugs, supporting the results obtained.

Assessment of body composition through DXA has the disadvantage of requiring costly technology, therefore, the use of anthropometric measurements, obtained through skinfolds, presents a feasible and low-cost alternative.

The trunk to arm and limb to trunk ratios may be used as indicators of preclinical lipodystrophy. No cutoffs were established to such values yet, requiring subsequent studies; however, continuous monitoring of these ratios may identify changes in body composition of these patients early.

Conflict of interest

All authors declare to have no conflict of interest.

References

1. Brady MT, Oleske JM, Williams PL, et al., Pediatric AIDS Clinical Trials Group219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010;53(1):86–94.
2. Matilda LH, Ramos JR AN, Heukelbach J, Hearst N, Brazilian Study Group on Survival of Children with AIDS. Continuing improvement in survival for children with acquired immunodeficiency syndrome in Brazil. Pediatr Infect Dis J. 2009;28(10):920–2.
3. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. Recomendações para Terapia Antiretroviral em Crianças e Adolescentes Infectados pelo HIV: manual de bolo/Ministério da Saúde, Secretaria de Vigilância em Saúde, Programa Nacional de DST e AIDS. – Brasília: Ministério da Saúde; 2009.
4. Carr A, Samaras K, Chrisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet. 1998;351:1881–3.
5. Miller TL. Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. AIDS. 2003;17 Suppl. 1:S130–40.
6. Valente AM, Reis AF, Machado DM, Succi RC, Chacra AR. Metabolic alterations in HIV-associated lipodystrophy syndrome. Arq Bras Endocrinol Metabol. 2005;49(6):871–81.
7. Brambilla F, Bricalli D, Sala N, et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS. 2001;15(18):2415–22.
8. Viganò A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active
antiretroviral therapy in HIV-infected children. JAIDS. 2003;32:482–9.
9. Sociedade Brasileira de Pediatria. Avaliação nutricional da criança e do adolescente – Manual de Orientação/Sociedade Brasileira de Pediatria. Departamento de Nutrologia. – São Paulo: Sociedade Brasileira de Pediatria, Departamento de Nutrologia; 2009. p. 112.
10. Marshall EA, Tanner JM. Growth and physiological development during adolescence. Annu Rev Med. 1975;19:283–300.
11. Centers for Disease Control. Revised classification system for human immunodeficiency virus (HIV) infection in children less than 13 years of age. MMWR. 1994;43:1–10.
12. Jaquet D, Lévine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome HIV-infected children. AIDS. 2000;14:2123–8.
13. World Health Organization. The WHO child growth standards. Growth reference, 5–19y. Geneva, Switzerland: World Health Organization; 2007.
14. Kwitterovich Jr PO. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab. 2003;93:4200–9.
15. Tresaco B, Bueno G, Pineda I, Moreno LA, Garagorri JM, Bueno M. Homeostatic model assessment (HOMA-IR) index cut-off values to identify the metabolic syndrome in children. J Physiol Biochem. 2005;61:381–8.
16. Heymsfield SB, Smith R, Aulet M, et al. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr. 1990;52:214–8.
17. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+-lymphocyte count and CD4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr. 2001;27(1):30–4.
18. Werner ML, Pone MV, Fonseca VM, Chaves CR. Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with HIV/AIDS receiving highly active antiretroviral therapy. J Pediatr (Rio J). 2010;86:27–32.
19. Sánchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel MJ, De José Gómez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr. 2005;164(5):271–6.
20. Rosso R, Parodi A, dAnunzio G, et al. Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol. 2007;157(5):655–9.
21. Ergun-Longmire B, Lin-Su K, Dunn AM, et al. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Endocr Pract. 2006;12(5):514–21.
22. Sarni RO, de Souza FL, Battistini TR, et al. Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relation with the antiretroviral therapy employed. J Pediatr (Rio J). 2009;85(4):329–34.
23. Spinola-Castro AM, Siviero-Miachon AA, da Silva MT, Guerra-Junior G. The use of growth hormone to treat endocrine-metabolic disturbances in acquired immunodeficiency syndrome (AIDS) patients. Arq Bras Endocrinol Metabol. 2008;52(5):818–22.
24. Patin RV, Palchetti CZ, Oliveira FLC. Criança e adolescente com SIDA. In: Palma D, Escrivão MAMS, Oliveira FLC, editors. Guia de nutrição clínica na infância e na adolescência. Barueri: Manole; 2009. p. 571–82.
25. Moyle GJ, Daar ES, Gertner JM, et al., Serono 9037 Study Team. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;35:367–75.
26. Gelato M, McNurlan M, Freedland E. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther. 2007;29:2269–88.
27. Chantry C, Byrd R, Englund J, Baker CJ, McKinney Jr RE, Pediatric Aids Clinical Trials Group Protocol 152 Study Team. Growth, survival and viral load in childhood HIV infection. Pediatr Infect Dis J. 2003;22:1033–9.
28. Stanley TL, Grinspoon SK. GH/GHRH axis in HIV lipodystrophy. Pituitary. 2009;12(2):143–52.
29. Zhao J, Brault JJ, Schild A, Goldberg AL. Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor. Autophagy. 2008;4(3):378–80.
30. Sandri M, Sandri C, Gilbert A, et al. FoxO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117:399–412.
31. Beregszászi M, Jaquet D, Lévine M, et al. Severe insulin resistance contrasting with mild anthropometric changes in the adipose tissue of HIV-infected children with lipohypertrophy. J Obes Relat Metab Disord. 2003;27:25–30.